BR0206917A - Uso de antagonistas de mglur5 para o tratamento de condições prurìticas - Google Patents

Uso de antagonistas de mglur5 para o tratamento de condições prurìticas

Info

Publication number
BR0206917A
BR0206917A BR0206917-2A BR0206917A BR0206917A BR 0206917 A BR0206917 A BR 0206917A BR 0206917 A BR0206917 A BR 0206917A BR 0206917 A BR0206917 A BR 0206917A
Authority
BR
Brazil
Prior art keywords
mglur5 antagonists
pruritic conditions
treat
treat pruritic
conditions
Prior art date
Application number
BR0206917-2A
Other languages
English (en)
Inventor
Fabrizio Gasparini
Laszlo Urban
Josef Gottfried Meingassner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0206917A publication Critical patent/BR0206917A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"USO DE ANTAGONISTAS DE MGLUR5 PARA O TRATAMENTO DE CONDIçõES PRURìTICAS". A presente invenção provê o uso de antagonistas de receptor de mGluR5 para o tratamento de condições pruríticas.
BR0206917-2A 2001-02-07 2002-02-06 Uso de antagonistas de mglur5 para o tratamento de condições prurìticas BR0206917A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103045.1A GB0103045D0 (en) 2001-02-07 2001-02-07 Organic Compounds
PCT/EP2002/001250 WO2002062323A2 (en) 2001-02-07 2002-02-06 Use of mglur5 antagonists for the treatment of pruritic conditions

Publications (1)

Publication Number Publication Date
BR0206917A true BR0206917A (pt) 2004-02-03

Family

ID=9908300

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206917-2A BR0206917A (pt) 2001-02-07 2002-02-06 Uso de antagonistas de mglur5 para o tratamento de condições prurìticas

Country Status (13)

Country Link
US (2) US20040106582A1 (pt)
EP (1) EP1359905B1 (pt)
JP (2) JP2004517947A (pt)
CN (1) CN1253151C (pt)
AT (1) ATE333869T1 (pt)
AU (1) AU2002231777A1 (pt)
BR (1) BR0206917A (pt)
CA (1) CA2433409C (pt)
DE (1) DE60213365T2 (pt)
ES (1) ES2271229T3 (pt)
GB (1) GB0103045D0 (pt)
PT (1) PT1359905E (pt)
WO (1) WO2002062323A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
GB0322612D0 (en) * 2003-09-26 2003-10-29 Novartis Ag Organic compounds
CN1870999A (zh) * 2003-10-31 2006-11-29 阿斯利康(瑞典)有限公司 炔烃ⅰ
WO2005044265A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
EP1677790A1 (en) * 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
RU2015111206A (ru) 2012-08-30 2016-10-20 Ниппон Синяку Ко., Лтд. Пиридиновое производное и лекарственное средство
UA120309C2 (uk) * 2015-06-03 2019-11-11 Ф. Хоффманн-Ля Рош Аг Етинільні похідні

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
FR2719044B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5534641A (en) * 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6774138B2 (en) * 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds

Also Published As

Publication number Publication date
DE60213365T2 (de) 2007-08-09
CA2433409A1 (en) 2002-08-15
PT1359905E (pt) 2006-11-30
EP1359905B1 (en) 2006-07-26
AU2002231777A1 (en) 2002-08-19
WO2002062323A3 (en) 2003-03-20
JP2004517947A (ja) 2004-06-17
GB0103045D0 (en) 2001-03-21
US20040106582A1 (en) 2004-06-03
WO2002062323A2 (en) 2002-08-15
JP2012131829A (ja) 2012-07-12
CN1253151C (zh) 2006-04-26
US20070265279A1 (en) 2007-11-15
EP1359905A2 (en) 2003-11-12
ATE333869T1 (de) 2006-08-15
DE60213365D1 (de) 2006-09-07
ES2271229T3 (es) 2007-04-16
CN1535143A (zh) 2004-10-06
CA2433409C (en) 2010-04-20

Similar Documents

Publication Publication Date Title
DE69732868D1 (de) Mittel gegen Juckreiz
TW200736231A (en) Substituted pyrimidines
BR0016878A (pt) Inibidores tricìclicos de cinases protéicas
CY1114554T1 (el) Ινδαζολια, βενζοτριαζολια και ν-αναλογα αυτων ως αναστολεις p38 κινασης
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
CL2007002389A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de obesidad, hirsutismo, hipertricosis y verrugas viricas.
UY27606A1 (es) Inhibidores de la fosfarasa
ATE411287T1 (de) Neue metallproteinaseinhibitoren
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE410235T1 (de) Behandlung von ballastwasser
TR200102448T2 (tr) COPD tedavisi için kontrollu salma formülasyonu.
ATE443044T1 (de) Tace inhibitoren
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
SE0302361D0 (sv) Inhibering av upptagning av monoamin
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.